Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 6/2011

01.06.2011 | Review Article

The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis

verfasst von: Prof. Bernd C. Kieseier

Erschienen in: CNS Drugs | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Multiple sclerosis (MS) is characterized by autoimmune inflammation and subsequent neurodegeneration. It is believed that early in the disease course, proinflammatory T cells that are activated in the periphery by antigen presentation cross the blood-brain barrier (BBB) into the CNS directed by various chemotaxic agents. However, to date, there has been no formal demonstration of a specific precipitating antigen. Once inside the CNS, activated T cells including T helper-1 (Th1), Th17, γδ and CD8+ types are believed to secrete proinflammatory cytokines. Decreased levels of Th2 cells also correlate with relapses and disease progression in MS, since Th2-derived cytokines are predominantly anti-inflammatory. In healthy tissue, inflammatory effects are opposed by specific subsets of regulatory T cells (Tregs) including CD4+, CD25+ and FoxP3+ cells that have the ability to downregulate the activity of proinflammatory T cells, allowing repair and recovery to generally follow inflammatory insult. Given their function, the pathogenesis of MS most likely involves deficits of Treg function, which allow autoimmune inflammation and resultant neurodegeneration to proceed relatively unchecked.
Interferons (IFNs) are naturally occurring cytokines possessing a wide range of anti-inflammatory properties. Recombinant forms of IFNβ are widely used as first-line treatment in relapsing forms of MS. The mechanism of action of IFNb is complex, involving effects at multiple levels of cellular function. IFNβ appears to directly increase expression and concentration of anti-inflammatory agents while downregulating the expression of proinflammatory cytokines. IFNβ treatment may reduce the trafficking of inflammatory cells across the BBB and increase nerve growth factor production, leading to a potential increase in neuronal survival and repair. IFNβ can also increase the number of CD56bright natural killer cells in the peripheral blood. These cells are efficient producers of anti-inflammatory mediators, and may have the ability to curb neuron inflammation. The mechanistic effects of IFNβ manifest clinically as reduced MRI lesion activity, reduced brain atrophy, increased time to reach clinically definite MS after the onset of neurological symptoms, decreased relapse rate and reduced risk of sustained disability progression.
The mechanism of action of IFNβ in MS is multifactorial and incompletely understood. Ongoing and future studies will increase our understanding of the actions of IFNβ on the immune system and the CNS, which will in turn aid advances in the management of MS.
Literatur
1.
Ferguson B, Matyszak MK, Esiri MM, et al. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393–9PubMedCrossRef
2.
Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278–85PubMedCrossRef
3.
Kuhlmann T, Lingfeld G, Bitsch A, et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002; 125: 2202–12PubMedCrossRef
4.
Haines JL, Ter-Minassian M, Bazyk A, et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex: the Multiple Sclerosis Genetics Group. Nat Genet 1996; 13: 469–71PubMedCrossRef
5.
Olsson T, Hillert J. The genetics of multiple sclerosis and its experimental models. Curr Opin Neurol 2008; 21: 255–60PubMedCrossRef
6.
Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple clerosis. N Engl J Med 2000; 343: 938–52PubMedCrossRef
7.
Gilden DH. Infectious causes of multiple sclerosis. Lancet Neurol 2005; 4: 195–202PubMed
8.
McCandless EE, Piccio L, Woerner BM, et al. Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis. Am J Pathol 2008; 172: 799–808PubMedCrossRef
9.
McCandless EE, Budde M, Lees JR, et al. IL-1R signaling within the central nervous system regulates CXCL12 expression at the blood-brain barrier and disease severity during experimental autoimmune encephalomyelitis. J Immunol 2009; 183: 613–20PubMedCrossRef
10.
11.
Fletcher JM, Lalor SJ, Sweeney CM, et al. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 2010; 162: 1–11PubMedCrossRef
12.
Venken K, Hellings N, Liblau R, et al. Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol Med 2010; 16: 58–68PubMedCrossRef
13.
Pettinelli CB, McFarlin DE. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2-T lymphocytes. J Immunol 1981; 127: 1420–3PubMed
14.
Zamvil S, Nelson P, Trotter J, et al. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature 1985; 317: 355–8PubMedCrossRef
15.
Aranami T, Yamamura T. Th17 cells and autoimmune encephalomyelitis (EAE/MS). Allergol Int 2008; 57: 115–20PubMedCrossRef
16.
Sun D, Whitaker JN, Huang Z, et al. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol 2001; 166: 7579–87PubMed
17.
Huseby ES, Liggitt D, Brabb T, et al. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med 2001; 194: 669–76PubMedCrossRef
18.
Sutton CE, Lalor SJ, Sweeney CM, et al. Interleukin-1 and IL-23 induce innate IL-17 production from gamma delta T cells, amplifying Th17 responses and autoimmunity. Immunity 2009; 31: 331–41PubMedCrossRef
19.
Yong VW, Chabot S, Stuve O, et al. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998; 51: 682–9PubMedCrossRef
20.
Dhib-Jabut. Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis. Neurology 2007; 68(22 Suppl. 3): S13–21CrossRef
21.
Arnason BG, Dayal A, Qu ZX, et al. Mechanisms of action of interferon-beta in multiple sclerosis. Springer Sem Immunopathol 1996; 18: 125–48CrossRef
22.
Segal BM, Dwyer BK, Shevach EM. An interleukin (IL)-10/ IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med 1998; 187: 537–46PubMedCrossRef
23.
Renkl AC, Wussler J, Ahrens T, et al. Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood 2005; 106: 946–55PubMedCrossRef
24.
van Boxel-Dezaire AH, Hoff SC, van Oosten BW, et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol 1999; 45: 695–703PubMedCrossRef
25.
Alvarez JI, Cayrol R, Prat A. Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta 2010; 1812: 252–64PubMed
26.
Waubant E, Goodkin DE, Gee L, et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 1999; 53: 1397–401PubMedCrossRef
27.
Leppert D, Ford J, Stabler G, et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998; 121: 2327–34PubMedCrossRef
28.
Waubant E, Goodkin D, Bostrom A, et al. IFNX lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 2003; 60: 52–7PubMedCrossRef
29.
Boz C, Ozmenoglu M, Velioglu S, et al. Matrix metallo-proteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clin Neurol Neurosurg 2006; 108: 124–8PubMedCrossRef
30.
Neumann H. Molecular mechanisms of axonal damage in inflammatory central nervous systems diseases. Curr Opin Neurol 2003; 16: 247–52CrossRef
31.
Trapp BD, Ransohoff R, Rudick R. Axonal pathology inmultiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999; 12: 295–302PubMedCrossRef
32.
Trapp BD, Ransohoff RM, Fisher E, et al. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 1999; 5: 48–57CrossRef
33.
Liuzzi G, Trojano M, Fanelli M, et al. Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult Scler 2002; 8: 222–8PubMedCrossRef
34.
Bitsch A, da Costa C, Bunkowski S, et al. Identification of macrophage populations expressing tumor necrosis factor-alphamRNA in acute multiple sclerosis. Acta Neuro-pathol 1998; 95: 373–7CrossRef
35.
Takeuchi M, Keino H, Suzuki J, et al. Possibility of inducing anterior chamber-associated immune deviation by TGF-beta2 treatment of monocytes isolated from Behçet’s patients. Exp Eye Res 2006; 83: 981–8PubMedCrossRef
36.
Muzio L, Martino G, Furlan R. Multifaceted aspects of inflammation in multiple sclerosis: the role of microglia. J Neuroimmunol 2007; 191: 39–44PubMedCrossRef
37.
Villoslada P, Hauser SL, Bartke I, et al. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J Exp Med 2000; 191: 1799–806PubMedCrossRef
38.
Flügel A, Matsumuro K, Neumann H, et al. Antiin-flammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration. Eur J Immunol 2001; 31: 11–22PubMedCrossRef
39.
Kohm AP, Carpentier PA, Anger HA, et al. Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol 2002; 169: 4712–6PubMed
40.
Zhang X, Koldzic DN, Izikson L, et al. IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+ CD4+ regulatory T cells. Int Immunol 2004; 16: 249–56PubMedCrossRef
41.
Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the life-span of mice. Nat Immunol 2007; 8: 191–7PubMedCrossRef
42.
Anderton SM, Liblau RS. Regulatory T cells in the control of inflammatory demyelinating diseases of the central nervous system. Curr Opin Neurol 2008; 21: 248–54PubMedCrossRef
43.
Kozovska ME, Hong J, Zang YC, et al. Interferon beta induces T-helper 2 immune deviation in MS. Neurology 1999; 53: 1692–7PubMedCrossRef
44.
Liu Z, Pelfrey CM, Cotleur A, et al. Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J Neuroimmunol 2001; 112: 153–62PubMedCrossRef
45.
Chen M, Chen G, Nie H, et al. Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T cells in MS. Eur J Immunol 2009; 39: 2525–36PubMedCrossRef
46.
Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 2008; 118: 1680–90PubMedCrossRef
47.
Shinohara ML, Kim JH, Garcia VA, et al. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity 2008; 29: 68–78PubMedCrossRef
48.
Prinz M, Schmidt H, Mildner A, et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008; 28: 675–86PubMedCrossRef
49.
Krakauer M, Sorensen P, Khademi M, et al. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Mult Scler 2008; 14: 622–30PubMedCrossRef
50.
Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008; 7: 796–804PubMedCrossRef
51.
Mirandola SR, Hallal DE, Farias AS, et al. Interferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis. Int Immunopharmacol 2009; 9: 824–30PubMedCrossRef
52.
Carrieri PB, Ladogana P, Di Spigna G, et al. Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders. Immunopharmacol Immunotoxicol 2008; 30: 1–9PubMedCrossRef
53.
Chabot S, Williams G, Yong VW. Microglial production of TNF-alpha is induced by activated T lymphocytes: involvement of VLA-4 and inhibition by interferonbeta-1b. J Clin Invest 1997; 100: 604–12PubMedCrossRef
54.
Muraro PA, Leist T, Bielekova B, et al. VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. J Neuroimmunol 2000; 111: 186–94PubMedCrossRef
55.
Muraro PA, Liberati L, Bonanni L, et al. Decreased integrin gene expression in patients with MS responding to interferon-beta treatment. J Neuroimmunol 2004; 150: 123–31PubMedCrossRef
56.
Avolio C, Filippi M, Tortorella C, et al. Serum MMP-9/ TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler 2005; 11: 441–6PubMedCrossRef
57.
Corsini E, Gelati M, Dufour A, et al. Effects of beta-IFN-1b treatment in MS patients on adhesion between PBMCs, HUVECs and MS-HBECs: an in vivo and in vitro study. J Neuroimmunol 1997; 79: 76–83PubMedCrossRef
58.
Gelati M, Corsini E, Dufour A, et al. Immunological effects of in vivo interferon-beta1b treatment in ten patients with multiple sclerosis: a 1-year follow-up. J Neurol 1999; 246: 569–73PubMedCrossRef
59.
Defazio G, Gelati M, Corsini E, et al. In vitro modulation of adhesion molecules, adhesion phenomena, and fluid phase endocytosis on human umbilical vein endothelial cells and brain-derived microvascular endothelium by IFN-beta 1a. J Interferon Cytokine Res 2001; 21: 267–72PubMedCrossRef
60.
Defazio G, Livrea P, Giorelli M, et al. Interferon beta-1a downregulates TNFalpha-induced intercellular adhesion molecule 1 expression on brain microvascular endothelial cells through a tyrosine kinase-dependent pathway. Brain Res 2000; 881: 227–30PubMedCrossRef
61.
Defazio G, Trojano M, Ribatti D, et al. ICAM 1 expression and fluid phase endocytosis of cultured brain microvascular endothelial cells following exposure to interferon beta-1a and TNFalpha. J Neuroimmunol 1998; 88: 13–20PubMedCrossRef
62.
Salama HH, Kolar OJ, Zang YC, et al. Effects of combination therapy of beta-interferon 1a and prednisone on serum immunologic markers in patients with multiple sclerosis. Mult Scler 2003; 9: 28–31PubMedCrossRef
63.
Leppert D, Waubant E, Bürk MR, et al. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996; 40: 846–52PubMedCrossRef
64.
Stüve O, Dooley NP, Uhm JH, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996; 40: 853–63PubMedCrossRef
65.
Jin S, Kawanokuchi J, Mizuno T, et al. Interferon-beta is neuroprotective against the toxicity induced by activated microglia. Brain Res 2007; 1179: 140–6PubMedCrossRef
66.
Biernacki K, Antel JP, Blain M, et al. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch Neurol 2005; 62: 563–8PubMedCrossRef
67.
Boutros T, Croze E, Yong VW. Interferon-beta is a potent promoter of nerve growth factor production by astrocytes. J Neurochem 1997; 69: 939–46PubMedCrossRef
68.
Saraste M, Irjala H, Airas L. Expansion of CD56bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci 2007; 28: 121–6PubMedCrossRef
69.
Vandenbark AA, Huan J, Agotsch M, et al. Interferon-beta-1a treatment increases CD56(bright) natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol 2009; 215(1–2): 125–8PubMedCrossRef
70.
Sellebjerg F, Datta P, Larsen J, et al. Gene expression analysis of interferon-beta treatment in multiple sclerosis. Mult Scler 2008; 14: 615–21PubMedCrossRef
71.
Weinstock-Guttman B, Bhasi K, Badgett D, et al. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: relationships to 5-year clinical outcomes in multiple sclerosis patients. J Neuroimmunol 2008; 205: 113–25PubMedCrossRef
72.
Kauffman MA, Yankilevich P, Barrero P, et al. Whole genome analysis of the action of interferon-beta. Int J Clin Pharmacol Ther 2009; 47: 328–57PubMed
73.
Balashov KE, Aung LL, Vaknin-Dembinsky A, et al. Interferon-β inhibits toll-like receptor 9 processing inmultiple sclerosis. Ann Neurol 2010; 68: 899–906PubMedCrossRef
74.
Paolillo A, Piattella MC, Pantano P, et al. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA. J Neurol 2004; 251: 432–9PubMedCrossRef
75.
Brex PA, Ciccarelli O, O’Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158–64PubMedCrossRef
76.
Tintoré M, Rovira A, Río J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006; 67: 968–72PubMedCrossRef
77.
Rudick R, Lee JC, Simon J, et al. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol 2006; 60: 236–42PubMedCrossRef
78.
Tomassini V, Paolillo A, Russo P, et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006; 253: 287–93PubMedCrossRef
79.
Zivadinov R, Sepcic J, Nasuelli D, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 70: 773–80PubMedCrossRef
80.
Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002; 59: 1412–20PubMedCrossRef
81.
Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003; 126: 770–82PubMedCrossRef
82.
Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989; 112: 1419–28
83.
Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demye-linating event in multiple sclerosis: CHAMPS Study Group. N Engl J Med 2000; 343: 898–904PubMedCrossRef
84.
Simon JH, Lull J, Jacobs LD, et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group. Neurology 2000; 55: 185–92
85.
Radue EW, Saharaian MA, Pace A, et al. The evaluation of black hole volume evolution as it relates to lesion load, extent of enhancement, and treatment with intramuscular interferon-beta-1a in two relapsing-remitting multiple sclerosis studies. Poster P608 presented at 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2006 Sep 27–30; Madrid
86.
Paty DW, Li DKB; UBC MS/MRI Study Group and IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662–7PubMedCrossRef
87.
PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498–504CrossRef
88.
Rudick RA, Fisher E, Lee JC, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS: Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53: 1698–704PubMedCrossRef
89.
Zivadinov R, Locatelli L, Cookfair D, et al. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult Scler 2007; 13: 490–501PubMed
90.
Barkhof F, Calabresi PA, Miller DH, et al. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009; 5: 256–66PubMedCrossRef
91.
Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285–94PubMedCrossRef
92.
Rudick R, Lee JC, Zhang H, et al. Progression of disability at 2 years predicts disability at 8 years: analysis from the phase 3 clinical trial of intramuscular interferon beta-1a. Poster P195 presented at 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2007 Oct 11–14; Prague
93.
IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655–61
94.
CHAMPIONS Study Group. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66: 678–84CrossRef
95.
Kinkel RP, Dontchev M, Tanner JP, et al. CHAMPIONS: 10-year follow-up after a clinically isolated syndrome in patients at high risk for developing multiple sclerosis. Mult Scler 2009; 15: S5–277, poster P446
96.
Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576–82PubMedCrossRef
97.
Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242–9PubMedCrossRef
98.
Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002; 59: 1496–506PubMedCrossRef
99.
Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453–60PubMedCrossRef
100.
Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001; 40: 539–51PubMedCrossRef
Metadaten
Titel
The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis
verfasst von
Prof. Bernd C. Kieseier
Publikationsdatum
01.06.2011
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 6/2011
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/11591110-000000000-00000

Weitere Artikel der Ausgabe 6/2011

CNS Drugs 6/2011 Zur Ausgabe

Adis Drug Profile

Fentanyl Pectin Nasal Spray

Current Opinion

Pharmacotherapy for Primary CNS Lymphoma

Adis Drug Evaluation

Oral Paliperidone

Leading Article

Suicidal Ideation during Antidepressant Treatment

Short Communication

Lower IQ is Associated with Decreased Clinical Response to Atomoxetine in Children and Adolescents with Attention-Deficit Hyperactivity Disorder

Review Article

Assessing QT Interval Prolongation and its Associated Risks with Antipsychotics

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise